Shots:

• Ginkgo is eligible to receive up front- R& D fees including milestones in the form of Selecta common stock- clinical & commercial milestones of ~$85M in cash along with royalties on sales
• The collaboration will utilize Ginkgo's cell programming platform & Selecta's ImmTOR platform to develop transformative enzymatic therapies. The collaboration builds on preclinical/clinical data from Selecta's P-II COMPARE trial for chronic refractory gout which supports ImmTOR for therapeutic benefit combined with immunogenic enzymatic therapies
• Selecta obtains rights to develop & commercialize therapeutic enzymes from Ginkgo's engineering platform for auto-immune diseases

 ­ | Ref: PR Newswire | Image: Selecta Bio